<DOC>
	<DOCNO>NCT00199134</DOCNO>
	<brief_summary>Find genetic signature de novo resistance letrozole adjuvant breast cancer ;</brief_summary>
	<brief_title>FRAGRANCE Part A Safety : Study Find Genetic Signature de Novo Resistance Letrozole</brief_title>
	<detailed_description>The aromatase inhibitor drug already approve treatment breast cancer adjuvant metastatic setting , demonstrate superiority compare hormone therapy agent tamoxifen . FRAGRANCE trial neoadjuvant hormone therapy activate September 2004 Jules Bordet Institute . The main objective study find genetic signature de novo resistance letrozole The standard dose letrozol , 2,5 mg/day , give orally 4 month previous definitive breast surgery . The advantage neoadjuvant set ) possibility directly evaluate response therapy , great value decide adjuvant treatment ; b ) increase chance perform breast conserving surgery ; c ) , tumor sample obtain treatment , identification predictive marker response resistance treatment , include genetic signature , obtain use microarray technology . Eligible patient woman early hormonal receptor positive breast cancer , contra-indication refusal administration chemotherapy The side effect letrozole already well know , include commonly hot flash , nausea vomiting , headache , arthralgia/myalgia , fatigue , oedema . After surgery , adjuvant treatment do accord standard practice Institute , consider possibility continue letrozole total least 5 year , satisfactory response achieve The first part trial include 49 patient . This trial soon become multicenter , multinational trial 160 patient .</detailed_description>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion : 1 . Female gender 2 . Postmenopausal ( age limit ) define : 1 . Radiationinduced menopause surgical bilateral oophorectomy , 2 . Women intact uterus . &gt; 55 year age ii . without menses last 5 year iii . £ 55 year age menses least last 12 month ( menses last 5 year ) postmenopausal level FSH c. Women without intact uterus . &gt; 55 year age ii . £ 55 year age postmenopausal level FSH 3 . Contraindications use neoadjuvant/adjuvant chemotherapy , refusal patient receive chemotherapy investigator believe patient suitable candidate protocol . 4. WHO performance status &lt; 1 5 . Histologicallyconfirmed ductal lobular operable adenocarcinoma breast ( stage I , II III ) 6 . Confirmed absence liver , lung bone metastasis . 7 . Primary tumor least 2 cm , measure clinically and/or radiologically 8 . Multifocal invasive tumor eligible , unless biopsy show ER positivity obtain tumor lesion . 9 . ERpositive and/or PgRpositive tumor , define accord immunohistochemistry ( i.e . &gt; 10 % positive cell immunostaining ) , woman young 70 year ; ERpositive PgRpositive tumor woman older 70 year . 10 . Fixed frozen sample primary tumor , obtain treatment , must available evaluation biological marker ( cDNA microarrays , EGFR , HER2 , intratumoral aromatase ) . 11 . No concurrent second malignancy , include contralateral breast cancer ( exception : adequately treat basal cell carcinoma skin situ carcinoma cervix ) . Any prior second malignancy must remission ³ 5 year . 12 . No serious illness medical condition include : History document congestive heart failure ; angina pectoris require antianginal medication ; evidence recent ( &lt; 6 month ) transmural infarction ECG ; poorly control hypertension ( e.g . systolic &gt; 180 mm Hg diastolic great 100 mm Hg ) ; clinically significant valvular heart disease ; highrisk uncontrolled arrhythmias . Chronic lung disease History significant neurological psychiatric disorder would prohibit understanding give informed consent , include psychotic disorder , mental retardation , dementia . Active concurrent infection 13 . No concurrent previous anticancer treatment allow 14 . Adequate organ function define : Neutrophils ³ 1.5 x 109/L Platelets ³ 100 x 109/L Bilirubin £ 1.5x upper limit normal ( ULN ) Transaminases £ 2.5x ULN Creatinine £ 1.5x ULN 15 . Normal leave ventricular ejection fraction echocardiography MUGA scan [ combination study ] 16 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 17 . Before patient registration/randomization , informed consent must give accord ICH/EU GCP , national/local regulation . Exclusion crieria : Non specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>neoadjuvant treatment</keyword>
</DOC>